Adverum Biotechnologies Stock Analysis

ADVM Stock  USD 4.93  0.47  8.70%   
Adverum Biotechnologies is undervalued with Real Value of 10.91 and Target Price of 29.71. The main objective of Adverum Biotechnologies stock analysis is to determine its intrinsic value, which is an estimate of what Adverum Biotechnologies is worth, separate from its market price. There are two main types of Adverum Biotechnologies' stock analysis: fundamental analysis and technical analysis.
The Adverum Biotechnologies stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Adverum Biotechnologies is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Adverum Stock trading window is adjusted to America/New York timezone.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adverum Biotechnologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
To learn how to invest in Adverum Stock, please use our How to Invest in Adverum Biotechnologies guide.

Adverum Stock Analysis Notes

About 13.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.78. Some equities with similar Price to Book (P/B) outperform the market in the long run. Adverum Biotechnologies recorded a loss per share of 5.95. The entity had not issued any dividends in recent years. The firm had 1:10 split on the 21st of March 2024. Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California. Adverum Biotechnlgs operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 188 people. For more info on Adverum Biotechnologies please contact Laurent Fischer at 650 656 9323 or go to https://adverum.com.

Adverum Biotechnologies Investment Alerts

Adverum Biotechnologies had very high historical volatility over the last 90 days
Adverum Biotechnologies has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 3.6 M. Net Loss for the year was (117.17 M) with loss before overhead, payroll, taxes, and interest of (67.22 M).
Adverum Biotechnologies currently holds about 235.84 M in cash with (90.9 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.37.
Adverum Biotechnologies has a frail financial position based on the latest SEC disclosures
Roughly 75.0% of the company shares are held by institutions such as insurance companies
Latest headline from MacroaxisInsider: Acquisition by Leonard Braden Michael of 25000 shares of Adverum Biotechnologies at 4.9356 subject to Rule 16b-3

Adverum Biotechnologies Upcoming and Recent Events

4th of April 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Adverum Largest EPS Surprises

Earnings surprises can significantly impact Adverum Biotechnologies' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2017-11-08
2017-09-30-0.29-0.32-0.0310 
2020-05-28
2020-03-31-0.27-0.31-0.0414 
2019-05-08
2019-03-31-0.27-0.230.0414 
View All Earnings Estimates

Adverum Biotechnologies Environmental, Social, and Governance (ESG) Scores

Adverum Biotechnologies' ESG score is a quantitative measure that evaluates Adverum Biotechnologies' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Adverum Biotechnologies' operations that may have significant financial implications and affect Adverum Biotechnologies' stock price as well as guide investors towards more socially responsible investments.

Adverum Stock Institutional Investors

Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Dimensional Fund Advisors, Inc.2024-12-31
311 K
Soleus Capital Management, L.p.2024-12-31
287.2 K
Regeneron Pharmaceuticals Inc2024-12-31
180.9 K
Nuveen Asset Management, Llc2024-12-31
172.4 K
Northern Trust Corp2024-12-31
152.6 K
Citadel Advisors Llc2024-12-31
149.1 K
Renaissance Technologies Corp2024-12-31
129.6 K
Morgan Stanley - Brokerage Accounts2024-12-31
114.8 K
Marshall Wace Asset Management Ltd2024-12-31
98 K
Bml Capital Management Llc2024-12-31
2.3 M
Tcg Crossover Management, Llc2024-12-31
1.8 M
Note, although Adverum Biotechnologies' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Adverum Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 112.33 M.

Adverum Profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets(0.61)(0.64)
Return On Capital Employed(0.96)(0.91)
Return On Assets(0.61)(0.64)
Return On Equity(1.61)(1.53)

Management Efficiency

Adverum Biotechnologies has return on total asset (ROA) of (0.2983) % which means that it has lost $0.2983 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7626) %, meaning that it created substantial loss on money invested by shareholders. Adverum Biotechnologies' management efficiency ratios could be used to measure how well Adverum Biotechnologies manages its routine affairs as well as how well it operates its assets and liabilities. As of the 26th of March 2025, Return On Tangible Assets is likely to drop to -0.64. In addition to that, Return On Capital Employed is likely to grow to -0.91. At this time, Adverum Biotechnologies' Intangible Assets are very stable compared to the past year.
Last ReportedProjected for Next Year
Book Value Per Share 7.45  11.14 
Tangible Book Value Per Share 7.45  11.11 
Enterprise Value Over EBITDA(0.58)(0.61)
Price Book Value Ratio 0.82  0.86 
Enterprise Value Multiple(0.58)(0.61)
Price Fair Value 0.82  0.86 
Enterprise Value6.7 B6.4 B
The leadership approach at Adverum Biotechnologies' fosters a culture of excellence and accountability. Our analysis examines how this culture influences financial outcomes and stock valuation.
Operating Margin
(29.22)
Beta
1.134
Return On Assets
(0.30)
Return On Equity
(0.76)

Technical Drivers

As of the 26th of March, Adverum Biotechnologies shows the Mean Deviation of 3.87, downside deviation of 5.52, and Risk Adjusted Performance of 0.0139. Adverum Biotechnologies technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Adverum Biotechnologies variance, value at risk, as well as the relationship between the Value At Risk and skewness to decide if Adverum Biotechnologies is priced correctly, providing market reflects its regular price of 4.93 per share. Given that Adverum Biotechnologies has jensen alpha of 0.0167, we suggest you to validate Adverum Biotechnologies's prevailing market performance to make sure the company can sustain itself at a future point.

Adverum Biotechnologies Price Movement Analysis

Execute Study
The output start index for this execution was nineteen with a total number of output elements of fourty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Adverum Biotechnologies middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Adverum Biotechnologies. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Adverum Biotechnologies Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Adverum Biotechnologies insiders, such as employees or executives, is commonly permitted as long as it does not rely on Adverum Biotechnologies' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Adverum Biotechnologies insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Laurent Fischer few days ago
Acquisition by Laurent Fischer of 200000 shares of Adverum Biotechnologies at 7.15 subject to Rule 16b-3
 
Leonard Braden Michael few days ago
Acquisition by Leonard Braden Michael of 30600 shares of Adverum Biotechnologies at 5.6133 subject to Rule 16b-3
 
Leonard Braden Michael six days ago
Acquisition by Leonard Braden Michael of 25000 shares of Adverum Biotechnologies at 4.9356 subject to Rule 16b-3
 
Leonard Braden Michael over a week ago
Acquisition by Leonard Braden Michael of 18000 shares of Adverum Biotechnologies at 4.6 subject to Rule 16b-3
 
Laurent Fischer over three weeks ago
Acquisition by Laurent Fischer of 25000 shares of Adverum Biotechnologies subject to Rule 16b-3
 
Leonard Braden Michael over three weeks ago
Acquisition by Leonard Braden Michael of 86802 shares of Adverum Biotechnologies at 4.4595 subject to Rule 16b-3
 
Leonard Braden Michael over three weeks ago
Acquisition by Leonard Braden Michael of 164886 shares of Adverum Biotechnologies at 4.0087 subject to Rule 16b-3
 
Svoronos Dawn over a month ago
Acquisition by Svoronos Dawn of 40000 shares of Adverum Biotechnologies subject to Rule 16b-3
 
Soparkar Peter over six months ago
Acquisition by Soparkar Peter of 450000 shares of Adverum Biotechnologies at 1.99 subject to Rule 16b-3
 
Scopa James Paul over six months ago
Acquisition by Scopa James Paul of 40000 shares of Adverum Biotechnologies subject to Rule 16b-3
 
Leonard Braden Michael over six months ago
Acquisition by Leonard Braden Michael of 85800 shares of Adverum Biotechnologies at 7.15 subject to Rule 16b-3
 
Kiss Szilard over six months ago
Acquisition by Kiss Szilard of 21040 shares of Adverum Biotechnologies at 7.32 subject to Rule 16b-3

Adverum Biotechnologies Outstanding Bonds

Adverum Biotechnologies issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Adverum Biotechnologies uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Adverum bonds can be classified according to their maturity, which is the date when Adverum Biotechnologies has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Adverum Biotechnologies Predictive Daily Indicators

Adverum Biotechnologies intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Adverum Biotechnologies stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Adverum Biotechnologies Corporate Filings

F4
20th of March 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
28th of February 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
27th of February 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
14th of February 2025
Other Reports
ViewVerify
13th of February 2025
Other Reports
ViewVerify
19th of December 2024
Other Reports
ViewVerify
17th of December 2024
Other Reports
ViewVerify
8K
18th of November 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify

Adverum Biotechnologies Forecast Models

Adverum Biotechnologies' time-series forecasting models are one of many Adverum Biotechnologies' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Adverum Biotechnologies' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Adverum Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Adverum Biotechnologies prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Adverum shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Adverum Biotechnologies. By using and applying Adverum Stock analysis, traders can create a robust methodology for identifying Adverum entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin(37.77)(39.66)
Operating Profit Margin(39.61)(41.59)
Net Loss(37.43)(39.30)
Gross Profit Margin(0.65)(0.62)

Current Adverum Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Adverum analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Adverum analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
29.71Strong Buy8Odds
Adverum Biotechnologies current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Adverum analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Adverum stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Adverum Biotechnologies, talking to its executives and customers, or listening to Adverum conference calls.
Adverum Analyst Advice Details

Adverum Stock Analysis Indicators

Adverum Biotechnologies stock analysis indicators help investors evaluate how Adverum Biotechnologies stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Adverum Biotechnologies shares will generate the highest return on investment. By understating and applying Adverum Biotechnologies stock analysis, traders can identify Adverum Biotechnologies position entry and exit signals to maximize returns.
Begin Period Cash Flow70.9 M
Common Stock Shares Outstanding10.1 M
Total Stockholder Equity83.5 M
Tax Provision-1.1 M
Property Plant And Equipment Net67 M
Cash And Short Term Investments96.5 M
Cash75 M
Accounts Payable1.9 M
Net Debt36 K
50 Day M A4.4518
Total Current Liabilities24.9 M
Other Operating Expenses127.6 M
Non Current Assets Total70.2 M
Non Currrent Assets Other1.2 M
Stock Based Compensation17.6 M
When determining whether Adverum Biotechnologies is a strong investment it is important to analyze Adverum Biotechnologies' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Adverum Biotechnologies' future performance. For an informed investment choice regarding Adverum Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adverum Biotechnologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
To learn how to invest in Adverum Stock, please use our How to Invest in Adverum Biotechnologies guide.
You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adverum Biotechnologies. If investors know Adverum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adverum Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(5.95)
Revenue Per Share
0.059
Quarterly Revenue Growth
(0.70)
Return On Assets
(0.30)
Return On Equity
(0.76)
The market value of Adverum Biotechnologies is measured differently than its book value, which is the value of Adverum that is recorded on the company's balance sheet. Investors also form their own opinion of Adverum Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Adverum Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adverum Biotechnologies' market value can be influenced by many factors that don't directly affect Adverum Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adverum Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adverum Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adverum Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.